Oxurion Overview
- Year Founded
-
1991
- Status
-
Public
- Employees
-
26
- Stock Symbol
-
OXUR
- Investments
-
4
Oxurion General Information
Description
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.
Contact Information
Website
www.oxurion.comCorporate Office
- Gaston Geenslaan 1
- 3001 Leuven
- Belgium
Corporate Office
- Gaston Geenslaan 1
- 3001 Leuven
- Belgium
Oxurion Stock Performance
As of 19-Nov-2026, Oxurion’s current market cap is $255K with 232M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $255K | 232M | 2.79M | $0.12 |
Oxurion Financials Summary
As of 30-Jun-2026, Oxurion has a trailing 12-month revenue of $1.34M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 13,159 | 13,243 | 12,916 | 13,123 |
| Revenue | 1,337 | 626 | 3 | 285 |
| EBITDA | (2,984) | (4,085) | 300 | (20,215) |
| Net Income | (4,035) | (4,205) | 129 | (20,526) |
| Total Assets | 3,922 | 4,493 | 5,926 | 7,240 |
| Total Debt | 13,143 | 13,440 | 11,787 | 13,634 |
Oxurion Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Oxurion Comparisons
Industry
Financing
Details
Oxurion Competitors (2)
One of Oxurion’s 2 competitors is Ora (Massachusetts), a Private Equity-Backed company based in Andover, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ora (Massachusetts) | Private Equity-Backed | Andover, MA | ||||
| Novartis | Corporation | Basel, Switzerland |
Oxurion Patents
Oxurion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023148016-A1 | Biomarker for plasma kallikrein inhibitor therapy response | Inactive | 04-Feb-2022 | ||
| WO-2023144030-A1 | Plasma kallikrein inhibitor therapy for anti-vegf sensitization | Inactive | 31-Jan-2022 | ||
| WO-2021198534-A1 | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease | Inactive | 04-Apr-2020 | ||
| WO-2021165206-A1 | Treatment of dry amd with integrin antagonists | Inactive | 19-Feb-2020 | ||
| AU-2019326932-A1 | Integrin antagonists | Inactive | 17-Aug-2018 | C07D471/04 |
Oxurion Signals
Oxurion Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Oxurion Investments & Acquisitions (4)
Oxurion’s most recent deal was a Merger/Acquisition with Axiodis CRO for . The deal was made on 04-Aug-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Axiodis CRO | 04-Aug-2025 | Merger/Acquisition | Consulting Services (B2B) | ||
| Oncurious | 12-Dec-2017 | Early Stage VC | Drug Discovery | ||
| Oncurious | 14-Apr-2015 | Joint Venture | Drug Discovery | ||
| ThromboGenics (TB-403 rights) | 05-Jun-2012 | Corporate Asset Purchase | Buildings and Property |
Oxurion ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Oxurion Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Axiodis CRO | Occitanie, France | 2006 |
Oxurion FAQs
-
When was Oxurion founded?
Oxurion was founded in 1991.
-
Where is Oxurion headquartered?
Oxurion is headquartered in Leuven, Belgium.
-
What is the size of Oxurion?
Oxurion has 26 total employees.
-
What industry is Oxurion in?
Oxurion’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Oxurion a private or public company?
Oxurion is a Public company.
-
What is Oxurion’s stock symbol?
The ticker symbol for Oxurion is OXUR.
-
What is the current market cap of Oxurion?
The current market capitalization of Oxurion is $255K.
-
What is Oxurion’s current revenue?
The trailing twelve month revenue for Oxurion is $1.34M.
-
Who are Oxurion’s competitors?
Ora (Massachusetts) and Novartis are competitors of Oxurion.
-
What is Oxurion’s annual earnings per share (EPS)?
Oxurion’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process